Covalent inhibitors: an opportunity for rational target selectivity
- PMID: 28609675
- DOI: 10.1016/j.cbpa.2017.05.008
Covalent inhibitors: an opportunity for rational target selectivity
Abstract
There is a resurging interest in compounds that engage their target through covalent interactions. Cysteine's thiol is endowed with enhanced reactivity, making it the nucleophile of choice for covalent engagement with a ligand aligning an electrophilic trap with a cysteine residue in a target of interest. The paucity of cysteine in the proteome coupled to the fact that closely related proteins do not necessarily share a given cysteine residue enable a level of unprecedented rational target selectivity. The recent demonstration that a lysine's amine can also be engaged covalently with a mild electrophile extends the potential of covalent inhibitors. The growing database of protein structures facilitates the discovery of covalent inhibitors while the advent of proteomic technologies enables a finer resolution in the selectivity of covalently engaged proteins. Here, we discuss recent examples of discovery and design of covalent inhibitors.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Reactive-cysteine profiling for drug discovery.Curr Opin Chem Biol. 2019 Jun;50:29-36. doi: 10.1016/j.cbpa.2019.02.010. Epub 2019 Mar 18. Curr Opin Chem Biol. 2019. PMID: 30897495 Free PMC article. Review.
-
Covalent inhibitors design and discovery.Eur J Med Chem. 2017 Sep 29;138:96-114. doi: 10.1016/j.ejmech.2017.06.019. Epub 2017 Jun 10. Eur J Med Chem. 2017. PMID: 28651155 Review.
-
Drug discovery for a new generation of covalent drugs.Expert Opin Drug Discov. 2012 Jul;7(7):561-81. doi: 10.1517/17460441.2012.688744. Epub 2012 May 19. Expert Opin Drug Discov. 2012. PMID: 22607458 Review.
-
Assessment of Tractable Cysteines for Covalent Targeting by Screening Covalent Fragments.Chembiochem. 2021 Feb 15;22(4):743-753. doi: 10.1002/cbic.202000700. Epub 2020 Nov 9. Chembiochem. 2021. PMID: 33030752
-
Following the Lead from Nature with Covalent Inhibitors.Chimia (Aarau). 2017 Oct 25;71(10):703-711. doi: 10.2533/chimia.2017.703. Chimia (Aarau). 2017. PMID: 29070414 Review.
Cited by
-
Curcumin-1,2,3-Triazole Conjugation for Targeting the Cancer Apoptosis Machinery.Molecules. 2020 Jul 5;25(13):3066. doi: 10.3390/molecules25133066. Molecules. 2020. PMID: 32635622 Free PMC article.
-
Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CLpro.J Biomol Struct Dyn. 2021 Aug;39(13):4936-4948. doi: 10.1080/07391102.2020.1782768. Epub 2020 Jun 24. J Biomol Struct Dyn. 2021. PMID: 32579061 Free PMC article.
-
Small-molecule covalent bond formation at tyrosine creates a binding site and inhibits activation of Ral GTPases.Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7131-7139. doi: 10.1073/pnas.1913654117. Epub 2020 Mar 16. Proc Natl Acad Sci U S A. 2020. PMID: 32179690 Free PMC article.
-
Advances in covalent drug discovery.Nat Rev Drug Discov. 2022 Dec;21(12):881-898. doi: 10.1038/s41573-022-00542-z. Epub 2022 Aug 25. Nat Rev Drug Discov. 2022. PMID: 36008483 Free PMC article. Review.
-
Current and Emerging Targeted Therapies for Acute Graft-Versus-Host Disease.BioDrugs. 2021 Jan;35(1):19-33. doi: 10.1007/s40259-020-00454-7. BioDrugs. 2021. PMID: 33201499 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources